Life sciences companies face an impending “tax policy trifecta” including potential TCJA expiration, U.S. trade and ...

Leadership is about fostering the conditions for others to succeed. Empathy shapes how teams function, how trust is built, ...

Improvements to the U.S. supply chain are needed to reduce shortages and protect American patients. Industry, academia, ...

For many professionals in the drug development industry, cell and gene therapies (CGT) represent a beacon of hope for patients in dire need of innovative treatments. This rapidly evolving field is ...

Business of Biotech MVP Allan Shaw is back to talk about the rise of China's biotech sector, and its evolution from fast follower to global innovation powerhouse.

QurAlis’ Kasper Roet describes the regulatory hurdles facing the RNA research space in the U.S. and why many companies are pursuing clinical work elsewhere.

QurAlis founder Kasper Roet explains how precision medicine can revolutionize neurogenerative disease therapeutics.

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why ...

On today's episode of the Business of Biotech, we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to ...

A Q&A with Darlena Le, PharmD, research fellow, Health Outcomes and Market Access Artificial intelligence is rapidly transforming various sectors, and healthcare market access is no exception. While ...